Mode
Text Size
Log in / Sign up
N/A N=100

A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas

Anorectal Fistulas

Enrolled (actual)
100
Serious AEs
6.0%
Results posted
Nov 2016
Primary outcome: Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Permacol collagen paste (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic - MITG
Primary completion
Dec 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Fistula Healing in Patients at 6 Months Following Surgery
56.7; 43.3
SECONDARY
Fistula Healing in Patients at 3 and 12 Months Following Surgery
53.2; 53.5; 46.8; 46.5
SECONDARY
Participant Response to Quality of Life EQ-5D Questionnaire
74; 77; 76; 72; 13; 7
SECONDARY
Fecal Incontinence
-1.0; -1.1; -0.9
SECONDARY
Patient Satisfaction Between the First and Last Post-operative Visit
37; 44; 39; 18; 8; 18
SECONDARY
Pain
29; 45; 47; 47; 53; 44

Summary

This will be a prospective, multi-center, post-market, single arm observational study to collect clinical outcome data on the use of Permacol™ Collagen Paste in the treatment of anorectal fistulas. The subjects will have baseline and day of surgery visits performed, and then subjects will return to the investigator for evaluation of defect and safety related morbidities at follow up visits scheduled at 1 month, 3 months, 6 months and 12 months post-surgery.

Eligibility Criteria

Key Inclusion Criteria

  • Male or female subjects age 18 or older
  • Subjects diagnosed with a solitary tract anorectal fistula of cryptoglandular origin

Key Exclusion Criteria

  • History or suspicion of Inflammatory Bowel Disease (i.e.Crohn's Disease, Ulcerative Colitis)
  • Subjects with secondary tracts, horseshoe fistulas, ano/recto-vaginal fistulas, or rectourethral fistulas
  • Indication of an actively infected fistula/abscess (acute sepsis)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01624350). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search